Cantor Fitzgerald Reiterates Overweight Rating on Axsome Therapeutics (AXSM)

Cantor Fitzgerald analyst Charles C. Duncan reiterated an Overweight rating and $153.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst commented, "We slightly reduced our projected revenue ramp for Sunosi, which slightly decreased our 2025/2026 EPS estimates. There is no change to our OW rating and $153 PT."

For an analyst ratings summary and ratings history on Axsome Therapeutics click here. For more ratings news on Axsome Therapeutics click here.

Shares of Axsome Therapeutics closed at $116.78 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating